New drug targets Gene-Amplified breast cancers in early trial
Disease control
Not yet recruiting
This study tests a new drug called SC-101 in 120 people with advanced breast cancer (triple-negative or hormone-receptor-positive) that has a specific gene change called NECTIN4 amplification. Participants receive the drug once a week through an IV. The goal is to see if the drug…
Phase: PHASE2 • Sponsor: Tianjin ConjuStar Biologics Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:32 UTC